Hong Kong stock movement: CANBRIDGE-B rose by 15.58%, with clear capital flow, market sentiment triggered volatility attention

Hong Kong Stock Movement CANBRIDGE-B, up 15.58%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry 3SBio down 3.69%. Based on recent news, On January 23, Sanfu Chemical announced that its invested new drug company, Sanfu Biomedical, has launched an IPO plan and completed over 300 million yuan in cash capital increase. Sanfu Biomedical focuses on new drug development in the fields of cancer, autoimmune, and ophthalmic diseases, which has attracted market attention and may impact 3SBio's stock price. Recently, the market has taken a cautious stance on the overall performance of the pharmaceutical industry, with investors uncertain about the progress of new drug development and market prospects, leading to pressure on 3SBio's stock price. Capital flow data shows that 3SBio's recent trading volume reached HKD 576 million, indicating high trading activity for the stock, but also reflecting outflow pressure. The pharmaceutical industry has shown weak performance recently, and investor sentiment is cautious. Kangfang Biologics down 3.86%, with a trading volume of HKD 526 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics down 2.87%. Based on recent key news: On January 23, a large number of Innovent's products entered medical insurance, enhancing market trust and brand influence, but profit margins were compressed, and the profit structure faced reconstruction, leading to stock price fluctuations. Source: Zhitong Finance On December 26, Novo Nordisk applied for a price reduction for semaglutide, with the maximum reduction approaching 50%. Eli Lilly's tirzepatide price plummeted, and the market expects an overall reduction of up to 80%, intensifying competition in the weight loss drug market, putting Innovent in a difficult position. Source: Wall Street Insight On January 16, the Anhui Provincial Medical Security Work Conference announced a national centralized procurement for biological drugs, causing Innovent's stock price to plunge in the afternoon, with a maximum drop of over 14%, closing down more than 10%. Source: Jinshi Data. The competition in the weight loss drug market has intensified, with evident capital outflow. Stocks with High Market Capitalization in the Industry BeiGene down 1.27%, with a market capitalization of HKD 310.6 billion, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation